Regeneron Pharmaceuticals, Inc. (REGN) Up 4.6% — Time to Turn Interest into Action?
Regeneron Pharmaceuticals, Inc. (REGN) extended its recent bullish activity, with shares advancing 4.58% on the session to close at $724.30. The stock gained $31.72 from the prior close of $692.58, marking a strong performance that underscores renewed upside momentum on the NASDAQ. Trading volume came in at 733,530 shares, running below the 90-day average of 1,065,806, suggesting that the latest move higher occurred on lighter-than-usual turnover. Even with that moderation in activity, the price action points to buyers steadily gaining ground and supporting higher levels.
At its current price, REGN is trading within sight of its 52-week peak of $791.49 set on Dec. 10, 2024, leaving the stock roughly $67 below that recent high. That relatively narrow gap highlights how the shares remain in the upper end of their annual range, reinforcing the impression of a stock that has been advancing rather than retreating. Within the broader large-cap healthcare and biopharma space — including peers such as Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), UnitedHealth Group (UNH), and Merck (MRK) — REGN’s latest percentage move stands out as particularly strong for the day, signaling firm bullish interest. Overall, the combination of a solid single-day percentage gain, proximity to the 52-week high, and ongoing upward trend positions REGN as one of the more assertive names in its sector from a near-term price-action perspective.
Why Regeneron Pharmaceuticals, Inc. Price is Moving Higher
Recent momentum in Regeneron Pharmaceuticals, Inc. is being driven primarily by a string of favorable clinical and strategic developments that investors view as long-term value creators. The company’s latest positive Phase 2 and Phase 3 trial readouts — including strong proof-of-concept data for its factor XI antibody candidates and successful LIBERTY-AFRS-AIMS results for Dupixent in allergic fungal rhinosinusitis — are reinforcing confidence in Regeneron’s research engine and future revenue streams. The FDA’s Priority Review for Dupixent, with a target action date of Feb. 28, 2026, provides a tangible regulatory catalyst that investors can point to as a potential driver of incremental growth. Against this backdrop, the recent pullback to $692.58, below an estimated fair value around $768, is being interpreted by many as an opportunity to buy into these catalysts at a discount.
At the same time, Regeneron’s recently announced collaboration with Tessera Therapeutics is adding another leg to the bullish narrative. The $150 million upfront payment, plus milestones and a 50:50 profit share on SERPINA1 gene-editing programs, signals a deliberate push into cutting-edge genetic medicine with meaningful long-term optionality. Solid profitability, highlighted by a profit margin above 30% and earnings per share of $41.77, underscores the company’s financial capacity to fund innovation without overextending its balance sheet. Even with short interest rising in recent weeks, the combination of resilient fundamentals, modest revenue growth, and visible clinical and regulatory milestones is fostering positive sentiment and supporting the stock’s upward bias relative to many large-cap peers in the broader health care space.
What is the Regeneron Pharmaceuticals, Inc. Rating - Should I Buy?
Weiss Ratings assigns REGN a C rating. Current recommendation is Hold. For investors, this places Regeneron Pharmaceuticals, Inc. in the middle of the pack — neither a clear standout nor a name to avoid outright — but with several quality markers that support its role as a core health care holding for more risk-aware portfolios.
The most notable strengths behind the C rating come from the Excellent Efficiency Index and Excellent Solvency Index. A profit margin of 32.13% and return on equity of 15.19% indicate that management is converting its research and development investments into solid profitability while maintaining a strong balance sheet. A forward P/E of 16.58 is relatively reasonable for a large-cap innovator in the Health Care space, giving investors exposure to a high-margin business without an extreme valuation premium.
At the same time, the rating acknowledges limitations. The Weak Total Return Index and Weak Volatility Index show that, despite strong fundamentals, REGN has not rewarded shareholders as consistently as higher-rated peers and has carried more price choppiness. Revenue growth of 0.90% is positive but modest, helping explain why the Growth component stands at a Fair level rather than higher.
Within its sector, Regeneron sits a notch below leaders like Eli Lilly and Company (LLY, B) and Johnson & Johnson (JNJ, B), but on par with other large players such as AbbVie Inc. (ABBV, C) and Merck & Co., Inc. (MRK, C). For investors comfortable with some volatility, REGN’s combination of strong efficiency, solid profitability and balance sheet strength makes it a candidate for closer watch within a diversified health care strategy.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for serious diseases across multiple therapeutic areas. Based in Tarrytown, New York, the company integrates genetics, antibody engineering and proprietary technology platforms to identify and advance novel drug candidates. Regeneron’s research-driven model centers on its VelociSuite technologies, which are designed to accelerate the creation of fully human antibodies and other biologic therapies that target specific disease pathways with high precision.
The company’s portfolio includes therapies for ophthalmology, immunology, oncology, hematology, cardiovascular and rare diseases, positioning it as a key player within the pharmaceuticals, biotechnology and life sciences industry. Regeneron is best known for its ophthalmology therapy for retinal diseases, as well as its immunology and inflammation treatments that address conditions such as atopic dermatitis, asthma and other allergic and inflammatory disorders. In oncology and hematology, the company is advancing a growing pipeline of bispecific antibodies and other targeted medicines that seek to harness the immune system to fight cancer.
Regeneron’s competitive advantages stem from its integrated research platform, deep expertise in human genetics and long-standing collaborations with leading health care and academic institutions. The company’s internal genetics center supports drug discovery by connecting genomic insights with clinical outcomes, helping to prioritize high-value targets. By maintaining control over much of the discovery and development process and selectively partnering for commercialization, Regeneron aims to sustain a robust pipeline of innovative biologic therapies that address unmet medical needs in global health care.
Investor Outlook
With Regeneron Pharmaceuticals, Inc. carrying a C (Hold) Weiss Rating, the stock appears reasonably balanced between risk and reward, offering potential for continued gains if execution and market conditions remain supportive. Investors may want to watch how the stock behaves around recent trading ranges, as well as broader Health Care sector trends that could drive a future upgrade or downgrade in its HOLD stance. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--